PIK3CA and head and neck squamous cell carcinoma: Co-targeting these pathways may effectively eliminate PI3K-independent CSCs, offering potential for novel anti-CSC therapeutic strategies in HNSCC, particularly for patients with PIK3CA amplification [123].